



NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034.
Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2020

(₹ in millions except per share data)

S.No.	Particulars	Quarter ended			Half Year ended		Year ended
		30 September 2020	30 June 2020	30 September 2019	30 September 2020	30 September 2019	31 March 2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
1	Revenue from operations (refer note 6)	8,022	5,634	4,857	13,656	9,780	19,150
2	Other income	257	187	332	444	542	1,074
3	Total income (1+2)	8,279	5,821	5,189	14,100	10,322	20,224
4	Expenses						
	Cost of materials consumed	866	1,214	787	2,080	1,455	3,290
	Purchases of stock-in-trade	1,082	432	315	1,514	395	1,278
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	1	143	90	144	102	(752)
	Employee benefits expense	1,237	952	1,024	2,189	1,956	3,750
	Finance costs	27	37	62	64	127	215
	Depreciation and amortisation expense	287	280	219	567	439	998
	Other expenses	2,072	1,182	1,298	3,254	2,616	5,758
	Total expenses	5,572	4,240	3,795	9,812	7,090	14,537
5	Profit before exceptional items and tax (3-4)	2,707	1,581	1,394	4,288	3,232	5,687
6	Exceptional items	-	-	-	-	-	-
7	Profit before tax (5-6)	2,707	1,581	1,394	4,288	3,232	5,687
8	Tax expense						
	(i) Current tax	718	425	328	1,143	738	1,271
	(ii) Income-tax for earlier years	-	-	-	-	-	40
	(iii) Deferred tax charge /(credit)	(50)	(65)	(111)	(115)	(111)	(205)
	Total tax expense	668	360	217	1,028	627	1,106
9	Profit for the period/year (7-8)	2,039	1,221	1,177	3,260	2,605	4,581
10	Other comprehensive income (net of tax)						
	A. Items that will not be reclassified subsequently to profit or loss:						
	Remeasurement of defined benefit plans	(19)	(20)	3	(39)	(46)	(79)
	Net gains / (losses) from investments in equity instruments designated at Fair value through other comprehensive income (FVTOCI)	91	19	6	110	(2)	(20)
	Income-tax relating to items that will not be reclassified to profit or loss	(11)	(1)	(4)	(12)	8	34
		61	(2)	5	59	(40)	(65)
	B. Items that will be reclassified subsequently to profit or loss:						
	Exchange differences on translation of foreign operations	(106)	23	4	(83)	66	(80)
		(106)	23	4	(83)	66	(80)
	Total other comprehensive income (net of tax) (A+B)	(45)	21	9	(24)	26	(145)
11	Total comprehensive income for the period/ year (9+10)	1,994	1,242	1,186	3,236	2,631	4,436
12	Profit for the period/year attributable to:						
	Owners of the Company	2,024	1,228	1,190	3,252	2,622	4,608
	Non-controlling interests	15	(7)	(13)	8	(17)	(27)
13	Other comprehensive income attributable to:						
	Owners of the Company	(45)	21	9	(24)	26	(145)
	Non-controlling interests	-	-	-	-	-	-
14	Total comprehensive income attributable to:						
	Owners of the Company	1,979	1,249	1,199	3,228	2,648	4,463
	Non-controlling interests	15	(7)	(13)	8	(17)	(27)
15	Paid-up equity share capital (face value of ₹2 each)	364	364	364	364	364	364
16	Other equity						37,371
17	Earnings per share (face value ₹2 each)						
	Basic (in ₹)	11.12	6.74	6.55	17.86	14.41	25.33
	Diluted (in ₹)	11.09	6.73	6.53	17.81	14.37	25.26
		(Non-annualised)	(Non-annualised)	(Non-annualised)	(Non-annualised)	(Non-annualised)	

See accompanying notes to the financial results.



NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034
Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2020

(₹ in millions except share data)

S.No.	Particulars	Quarter ended			Half Year ended		Year ended
		30 September 2020	30 June 2020	30 September 2019	30 September 2020	30 September 2019	31 March 2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
1	Revenue from operations	4,789	5,322	4,577	10,111	9,224	17,902
2	Other income	272	199	339	471	543	1,238
3	Total income (1+2)	5,061	5,521	4,916	10,582	9,767	19,140
	Expenses						
4	Cost of materials consumed	866	1,214	787	2,080	1,455	3,290
	Purchases of stock-in-trade	1,068	433	284	1,501	288	1,239
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0*	97	110	97	152	(559)
	Employee benefits expense	1,048	900	979	1,948	1,859	3,561
	Finance costs	27	33	57	60	119	206
	Depreciation and amortisation expense	284	276	216	560	432	981
	Other expenses	903	952	1,047	1,855	2,143	4,591
	Total expenses	4,196	3,905	3,480	8,101	6,448	13,309
5	Profit before exceptional items and tax (3-4)	865	1,616	1,436	2,481	3,319	5,831
6	Exceptional items	-	-	-	-	-	-
7	Profit before tax (5-6)	865	1,616	1,436	2,481	3,319	5,831
	Tax expense						
	(i) Current tax	206	414	325	620	731	1,251
	(ii) Income-tax for earlier years	-	-	-	-	-	40
	(ii) Deferred tax charge /(credit)	(50)	(65)	(111)	(115)	(111)	(205)
	Total tax expense	156	349	214	505	620	1,086
9	Profit for the period/ year (7-8)	709	1,267	1,222	1,976	2,699	4,745
	Other comprehensive income (net of tax)						
	Items that will not be reclassified to profit or loss:						
	Remeasurement of defined benefit plans	(19)	(20)	3	(39)	(46)	(79)
	Net gains / (losses) from investments in equity instruments designated at FVTOCI	91	28	3	119	(9)	(19)
	Income-tax relating to items that will not be reclassified to profit or loss	(11)	(3)	(3)	(14)	10	34
	Total other comprehensive income (net of tax)	61	5	3	66	(45)	(64)
11	Total comprehensive income for the period/ year (9+10)	770	1,272	1,225	2,042	2,654	4,681
12	Paid-up equity share capital (face value of ₹2 each)	364	364	364	364	364	364
13	Other equity						38,331
	Earnings per share (face value ₹2 each)						
	Basic (in ₹)	3.89	6.96	6.72	10.85	14.84	26.08
	Diluted (in ₹)	3.88	6.94	6.70	10.82	14.79	26.01
		(Non-annualised)	(Non-annualised)	(Non-annualised)	(Non-annualised)	(Non-annualised)	

*The numbers are rounded off to nearest million.
See accompanying notes to the financial results.



NATCO Pharma Limited

Standalone Balance Sheet:

(₹ in millions)

	As at 30 September 2020 (Unaudited)	As at 31 March 2020 (Audited)
I. Assets		
(1) Non-current assets		
(a) Property, plant and equipment	16,666	15,657
(b) Capital work-in-progress	4,503	5,178
(c) Intangible assets	95	88
(d) Investment in subsidiaries	1,387	1,025
(e) Financial assets		
(i) Investments	1,420	836
(ii) Loans	397	684
(iii) Other financial assets	43	41
(f) Other non-current assets	554	559
Total non-current assets	25,065	24,068
(2) Current assets		
(a) Inventories	6,434	5,244
(b) Financial assets		
(i) Investments	122	50
(ii) Trade receivables	6,504	5,367
(iii) Cash and cash equivalents	151	79
(iv) Bank balances other than (iii) above	2,575	462
(v) Loans	71	81
(vi) Other financial assets	5,163	8,612
(c) Other current assets	2,872	2,504
Total current assets	23,892	22,399
Total assets	48,957	46,467
II. EQUITY AND LIABILITIES		
(1) Equity		
(a) Equity share capital	364	364
(b) Other equity	40,072	38,331
Total of equity	40,436	38,695
(2) Liabilities		
(A) Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	9	9
(ii) Other financial liabilities	9	8
(b) Provisions	1,051	902
(c) Deferred tax liabilities, (net)	328	256
Total non-current liabilities	1,397	1,175
(B) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	4,312	3,131
(ii) Trade payables		
- Dues of micro and small enterprises	21	21
- Dues of creditors other than micro and small enterprises	1,719	2,321
(iii) Other financial liabilities	799	812
(b) Other current liabilities	155	122
(c) Provisions	118	105
(d) Current tax liabilities, (net)	-	85
Total current liabilities	7,124	6,597
Total liabilities	8,521	7,772
Total equity and liabilities	48,957	46,467



NATCO Pharma Limited

Standalone Statement of Cash Flows:

(₹ in millions)

	Half Year ended	
	30 September 2020 (Unaudited)	30 September 2019 (Unaudited)
Cash flows from operating activities:		
Profit before tax	2,481	3,319
Adjustments for:		
Depreciation and amortisation expense	560	432
Finance costs	60	119
Share based payment expense	110	90
Interest income	(302)	(439)
Allowance for credit losses	65	-
Bad debts written off	-	21
Liabilities written back	-	(29)
Profit on sale of property, plant and equipment, (net)	(125)	-
Unrealised foreign exchange loss/(gain), (net)	(15)	(124)
Operating profit before working capital changes	2,834	3,389
Changes in working capital:		
Changes in inventories	(1,191)	174
Changes in trade receivables	(1,135)	(415)
Changes in loans, financial and other assets	(360)	(544)
Changes in trade payables	(602)	(518)
Changes in provisions, financial and other liabilities	180	819
Cash (used in)/ generated from operating activities	(274)	2,905
Income taxes paid, (net)	(532)	(755)
Net cash (used in)/ generated from operating activities	(806)	2,150
Cash flows from investing activities:		
Purchase of property, plant and equipment	(951)	(1,696)
Proceeds from sale of property, plant and equipment	173	-
Acquisition of intangible assets	(29)	(15)
Investments in subsidiaries	(73)	(25)
Loans given to subsidiary companies	-	(7)
Proceeds from sale of investments	44	1,200
Purchase of investments	(583)	(4)
Movement in other bank balances, (net)	(2,113)	1,260
Interest received	539	614
Deposits with financial institutions	3,212	(1,956)
Net cash from/ (used in) investing activities	219	(629)
Cash flows from financing activities:		
Proceeds from issue of shares*	0	0
Buy-back of equity shares, including transaction costs	-	(538)
Contribution from shareholders	-	474
Net proceeds from short-term borrowings	1,135	(850)
Dividends paid including dividend distribution tax	(411)	(546)
Interest paid	(60)	(121)
Payment of lease liability including interest	(5)	-
Net cash from/ (used in) financing activities	659	(1,581)
Net increase / (decrease) in cash and cash equivalents	72	(60)
Cash and cash equivalents at the beginning of the year	79	115
Cash and cash equivalents at the end of the year	151	55
Debt reconciliation statement in accordance with Ind AS 7:-		
Current borrowings:		
Opening balance	3,123	3,845
Proceeds from/ (repayment of) borrowings, net	1,135	(850)
Non-cash items (Foreign exchange changes)	51	-
	4,309	2,995
Lease liabilities:		
Opening balance	17	-
Payment of lease liabilities	(5)	-
Interest accrued on lease liabilities*	0	-
	12	-

*The numbers are rounded off to nearest million.



NATCO Pharma Limited

Notes to the unaudited standalone financial results:

- 1) The unaudited standalone financial results of NATCO Pharma Limited ("the Company") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2) The unaudited standalone financial results for the quarter and half year ended 30 September 2020 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 12 November 2020.
- 3) The results of the Company for the quarter and half year ended 30 September 2020, have been reviewed by the Statutory auditors and they have issued an unqualified review report on the same. The review report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
- 4) Where financial results contain both consolidated and standalone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly, segment information has been presented in the consolidated financial results.
- 5) During the quarter ended 30 September 2020, 118,360 equity shares of ₹ 2 each, fully-paid up, were allotted upon exercise of the vested stock options pursuant to the ESOP 2015 scheme, resulting in an increase in the paid-up share capital of ₹ 0.24 million and securities premium account of ₹ 57.73 million.
- 6) The Company has considered internal and external information while assessing the recoverability of its assets upto the date of approval of these financial results by the Board of Directors. Based on such assessment and considering the current economic indicators, the Company expects to recover the carrying amount of these assets. The Board of Directors has also considered the impact of COVID-19 on the business for the foreseeable future and have concluded that the Company has sufficient resources to continue as a going concern. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes to future economic conditions.
- 7) The Board of Directors at their meeting held on 12 November 2020 have recommended an interim dividend of ₹3 per equity share of ₹2 each for the quarter and half year ended 30 September 2020.
- 8) Figures for the previous periods/ year have been regrouped, wherever necessary, to correspond with the figures of the current period.

**By order of the Board
For NATCO Pharma Limited**

Place: Hyderabad
Date: 12 November 2020

V C Nannapaneni
Chairman and Managing Director
(DIN: 00183315)



NATCO Pharma Limited

Consolidated Balance Sheet:

(₹ in millions)

	As at 30 September 2020 (Unaudited)	As at 31 March 2020 (Audited)
I Assets		
(1) Non-current assets		
(a) Property, plant and equipment	16,756	15,756
(b) Capital work-in-progress	4,536	5,180
(c) Intangible assets	95	88
(d) Financial assets		
(i) Investments	1,790	836
(ii) Loans	163	161
(iii) Other financial assets	43	42
(e) Other non-current assets	554	559
Total non-current assets	23,937	22,622
(2) Current assets		
(a) Inventories	6,713	5,580
(b) Financial assets		
(i) Investments	1,221	287
(ii) Trade receivables	6,431	5,513
(iii) Cash and cash equivalents	2,062	198
(iv) Bank balances other than (iii) above	2,575	462
(v) Loans	74	84
(vi) Other financial assets	5,138	8,588
(c) Other current assets	2,908	2,544
Total current assets	27,122	23,256
Total assets	51,059	45,878
II EQUITY AND LIABILITIES		
(1) Equity		
(a) Equity share capital	364	364
(b) Other equity	40,293	37,371
Equity attributable to owners of the Company	40,657	37,735
(c) Non-controlling interest	135	112
Total equity	40,792	37,847
(2) Liabilities		
(A) Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	9	9
(ii) Other financial liabilities	9	8
(b) Provisions	1,051	902
(c) Deferred tax liabilities, net	328	259
Total non-current liabilities	1,397	1,178
(B) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	4,328	3,150
(ii) Trade payables		
- Dues of micro and small enterprises	21	21
- Dues of creditors other than micro and small enterprises	2,911	2,533
(iii) Other financial liabilities	833	825
(b) Other current liabilities	158	134
(c) Provisions	118	105
(d) Current tax liabilities, net	501	85
Total current liabilities	8,870	6,853
Total liabilities	10,267	8,031
Total equity and liabilities	51,059	45,878



NATCO Pharma Limited

Consolidated Statement of Cash Flows:

(₹ in millions)

	Half Year ended	
	30 September 2020 (Unaudited)	30 September 2019 (Unaudited)
Cash flows from operating activities:		
Profit before tax	4,288	3,232
Adjustments for:		
Depreciation and amortisation expense	567	439
Finance cost	64	127
Share based payment expense	110	90
Interest income	(296)	(427)
Allowance for credit loss	65	-
Bad debts written off	-	21
Liabilities written back	-	(29)
Profit on sale of property, plant and equipment, net	(125)	-
Unrealised foreign exchange gain, net	(15)	(124)
Operating profit before working capital changes	4,658	3,329
Changes in working capital:		
Changes in inventories	(1,134)	134
Changes in trade receivables	(917)	(430)
Changes in loans, financial and other assets	(360)	(520)
Changes in trade payables	376	(613)
Changes in provisions, financial and other liabilities	191	832
Cash generated from operating activities	2,814	2,732
Income taxes paid, net	(555)	(766)
Net cash generated from operating activities	2,259	1,966
Cash flows from investing activities:		
Purchase of property, plant and equipment	(979)	(1,667)
Proceeds from sale of property, plant and equipment	173	-
Acquisition of intangible assets	(29)	(15)
Purchase of investments	(1,825)	(7)
Proceeds from sale of investments	44	1,200
Movement in other bank balances, net	(2,113)	1,260
Interest received	535	602
Deposits with financial institutions	3,212	(1,956)
Net cash used in investing activities	(982)	(583)
Cash flows from financing activities		
Proceeds from issue of shares*	0	0
Buy-back of equity shares, including transaction costs	-	(538)
Contribution from shareholders	-	474
Proceeds from non-controlling interest	15	3
Net proceeds from short-term borrowings	1,135	(849)
Payment of lease liability including interest	(5)	-
Dividends paid including dividend distribution tax	(411)	(546)
Interest paid	(64)	(131)
Net cash from/ (used in) financing activities	670	(1,587)
Net increase / (decrease) in cash and cash equivalents	1,947	(204)
Cash and cash equivalents at beginning of the year	198	283
Effect of currency translation adjustment	(83)	69
Cash and cash equivalents at the end of the year	2,062	148
Debt reconciliation statement in accordance with Ind AS 7:-		
Current borrowings:		
Opening balance	3,142	3,863
Proceeds from/ (repayment of) borrowings, net	1,135	(849)
Non-cash items (Foreign exchange changes)	48	-
	4,325	3,014
Lease liabilities:		
Opening balance	17	-
Payment of lease liabilities	(5)	-
Interest accrued on lease liabilities*	0	-
	12	-

*The numbers are rounded off to nearest million.



NATCO Pharma Limited

Segment reporting:

(₹ in millions except share data)

S.No.	Particulars	Quarter ended			Half year ended		Year ended
		30 September 2020	30 June 2020	30 September 2019	30 September 2020	30 September 2019	31 March 2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment revenue						
	a. Pharmaceuticals	8,021	5,634	4,857	13,655	9,780	19,150
	b. Agro chemicals	1	-	-	1	-	-
	Total revenue from operations	8,022	5,634	4,857	13,656	9,780	19,150
	Add: Unallocated	-	-	-	-	-	-
2	Segment results						
	a. Pharmaceuticals	2,738	1,618	1,456	4,356	3,359	5,902
	b. Agro chemicals	(4)	-	-	(4)	-	-
	Total segment result	2,734	1,618	1,456	4,352	3,359	5,902
	Less:						
	a. Finance cost	(27)	(37)	(62)	(64)	(127)	(215)
	b. Net unallocated (income)/expenditure	-	-	-	-	-	-
	Total profit before tax	2,707	1,581	1,394	4,288	3,232	5,687
3	Segment assets						
	a. Pharmaceuticals	46,291	44,871	43,401	46,291	43,401	43,404
	b. Agro chemicals	1,757	1,610	729	1,757	729	1,351
	Total segment assets	48,048	46,481	44,130	48,048	44,130	44,755
	Add:						
	a. Unallocated	3,011	1,305	490	3,011	490	1,123
	Total assets	51,059	47,786	44,620	51,059	44,620	45,878
4	Segment liabilities						
	a. Pharmaceuticals	5,041	4,653	3,438	5,041	3,438	4,467
	b. Agro chemicals	60	83	38	60	38	61
	Total segment liabilities	5,101	4,736	3,476	5,101	3,476	4,528
	Add:						
	a. Unallocated	5,166	3,885	3,222	5,166	3,222	3,503
	Total liabilities	10,267	8,621	6,698	10,267	6,698	8,031

Until the previous year, the operating segment of the Group was identified to be "Pharmaceuticals", as the Chief Operating Decision Maker ('CODM') reviewed the business performance accordingly. The Group has commenced the Agri Chemicals division and the management expects completion of substantial portion of construction activity in the current financial year followed by commencement of commercial operations in near future. The CODM has started reviewing the Agri Chemicals segment from the current period. Hence, the Group has disclosed Agri Chemicals as a separate reportable segment and has restated previously reported information to conform to current period presentation.



NATCO Pharma Limited

Notes to unaudited consolidated financial results:

- 1) The unaudited consolidated financial results of NATCO Pharma Limited ("the Company") and its subsidiaries (together referred as "the Group") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2) The unaudited consolidated financial results for the quarter and half year ended 30 September 2020 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 12 November 2020.
- 3) The results of the Group for the quarter and half year ended 30 September 2020, have been reviewed by the Statutory auditors and they have issued an unqualified review report on the same. The review report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
- 4) The unaudited consolidated financial results for the quarter and half year ended 30 September 2020 include financial results of the following subsidiaries:

Sr. No	Name of the Entity
1	NATCO Pharma Inc., United States of America
2	Time Cap Overseas Limited, Mauritius
3	NATCO Farma do Brasil Ltda, Brazil (subsidiary of Time Cap Overseas Limited)
4	NATCO Pharma (Canada) Inc., Canada
5	NATCO Pharma Asia Pte. Ltd., Singapore
6	NATCO Pharma Australia PTY Ltd., Australia
7	NATCO Lifesciences Philippines Inc., Philippines

- 5) The Group has considered internal and external information while assessing the recoverability of its assets upto the date of approval of these financial results by the Board of Directors. Based on such assessment and considering the current economic indicators, the Group expects to recover the carrying amount of these assets. The Board of Directors has also considered the impact of COVID-19 on the business for the foreseeable future and have concluded that the Group has sufficient resources to continue as a going concern. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Group will continue to closely monitor any material changes to future economic conditions.
- 6) Revenue from operations for the quarter and half year ended 30 September 2020 includes an income from settlement of claims received by Natco Pharma (Canada) Inc., Canada, a subsidiary of Natco Pharma Limited under a confidential settlement agreement entered with a party for a product in Canada.
- 7) The unaudited standalone financial results, for the quarter and half year ended 30 September 2020 can be viewed on the website of the Company, NSE and BSE at www.natcopharma.co.in, www.nseindia.com, and www.bseindia.com respectively. Information of unaudited standalone financial results of the Company in terms of Regulation 47(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as under:

(₹ in millions)

Particulars	Quarter ended			Half Year ended		Year ended
	30 Sep 2020	30 June 2020	30 Sep 2019	30 Sep 2020	30 Sep 2019	31 March 2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total revenue from operations	4,789	5,322	4,577	10,111	9,224	17,902
Profit before tax	865	1,616	1,436	2,481	3,319	5,831
Net profit for the period/ year	709	1,267	1,222	1,976	2,699	4,745
Total comprehensive income	770	1,272	1,225	2,042	2,654	4,681

- 8) The Board of Directors in their meeting held on 12 November 2020 have recommended an interim dividend of ₹3 per equity share of ₹ 2 each for the quarter ended 30 September 2020.
- 9) During the quarter ended 30 September 2020, 118,360 equity shares of ₹ 2 each, fully-paid up, were allotted upon exercise of the vested stock options pursuant to the ESOP 2015 scheme, resulting in an increase in the paid-up share capital of ₹ 0.24 million and securities premium account of ₹ 57.73 million.
- 10) Figures for the previous periods/ year have been regrouped, wherever necessary, to correspond with the figures of the current period.

**By order of the Board
For NATCO Pharma Limited**

Place: Hyderabad
Date: 12 November 2020

V C Nannapaneni
Chairman and Managing Director
(DIN: 00183315)